Tesamorelin Online Buyer's Guide: Egrifta vs Compounded, Pricing, and How to Get a Prescription in 2026

The short answer

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to release more of the body's own growth hormone in a natural pulsatile pattern. The brand Egrifta is FDA-approved for HIV-associated abdominal lipodystrophy; compounded tesamorelin is not FDA approved. The molecule is prescribed off-label for visceral fat reduction, age-related growth hormone optimization, and body composition goals.

Branded Egrifta runs approximately $2,000 to $3,500 per month at standard dosing. The same active molecule compounded by a 503A pharmacy is $200 per 24mg vial under a prescription at Rx Peps Direct. For cash-pay patients (most non-HIV indications) compounded tesamorelin is the practical choice. Rx Peps Direct prescribes tesamorelin at 24mg and the tesamorelin/ipamorelin blend via a licensed U.S. 503A compounding pharmacy, with a $39 medical review that covers up to three different peptides per order.

What tesamorelin actually is

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, the hypothalamic peptide that signals the pituitary gland to release growth hormone. The molecule is a stabilized 44-amino-acid peptide engineered for greater stability and longer half-life than native GHRH while preserving the receptor binding activity.

When tesamorelin binds GHRH receptors on the anterior pituitary, it triggers the release of stored growth hormone into circulation in a natural pulsatile pattern. The body's own feedback mechanisms remain intact, so growth hormone release stays regulated rather than crossing into supraphysiological excess. This is the mechanistic argument for GHRH analogs over recombinant human growth hormone (HGH): GHRH analogs amplify the body's own production within natural feedback control, while recombinant HGH bypasses feedback entirely.

Tesamorelin received FDA approval in 2010 as Egrifta (tesamorelin for injection) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The approval was based on phase III trials showing meaningful visceral adipose tissue reduction in the HIV lipodystrophy population. The same mechanism that reduces visceral fat in HIV patients works in non-HIV patients with elevated visceral adiposity, which drives the off-label use.

Egrifta vs compounded tesamorelin

The compounded versus branded question is the most common point of confusion for patients new to tesamorelin. The biochemistry is the same; the regulatory frame, formulation specifics, and price differ significantly.

Egrifta is the branded FDA-approved product manufactured by Theratechnologies. It is supplied as a powder plus diluent in a specific vial size with a specific reconstitution and dosing protocol. Egrifta has indication- specific FDA approval (HIV-associated abdominal lipodystrophy) and a published clinical trial evidence base supporting the approval. Retail pricing in the United States runs approximately $2,000 to $3,500 per month at the FDA-approved 2mg daily dose, depending on pharmacy and insurance.

Compounded tesamorelin is the same active pharmaceutical ingredient (tesamorelin acetate) prepared by a 503A compounding pharmacy under Section 503A of the Federal Food, Drug, and Cosmetic Act. The compounded product is prepared under a patient-specific prescription written by a licensed clinician documenting the indication. Compounded tesamorelin is not FDA approved as a drug product (compounded medications generally are not), but a pharmacy can legally compound and supply it under the 503A pathway.

The clinical question for the patient: does compounded tesamorelin produce the same effect as Egrifta? The active molecule is the same, the receptor binding is the same, and the biological response is the same when dose and route match. Differences are in formulation (vial size, stabilizers, reconstitution protocol) rather than in mechanism. For the off-label indications most patients seek (visceral fat reduction, GH optimization), the clinical observation base supports the same outcomes with compounded versus branded.

The economic question for the patient: insurance generally does not cover Egrifta for non-HIV indications (the off-label uses that drive most patient interest). At cash-pay prices, $2,000+ per month for branded versus about $83 per week for compounded at 2mg is a meaningful difference. Most non-HIV patients choose compounded.

Tesamorelin for visceral fat reduction

The strongest clinical evidence for tesamorelin is in visceral fat reduction. The Egrifta phase III trials in HIV patients with lipodystrophy showed average visceral adipose tissue (VAT) reduction of 15 to 18 percent over 26 weeks at the FDA-approved 2mg daily dose. The reduction is selective for visceral fat (the metabolically active fat that wraps around abdominal organs); subcutaneous fat is not preferentially reduced.

The mechanism is growth hormone-mediated lipolysis. Increased GH secretion drives breakdown of visceral fat, which is particularly GH-responsive. The clinical effect is most pronounced in patients with elevated baseline visceral adiposity. Patients with primarily subcutaneous adiposity see smaller relative effects.

Off-label use in non-HIV patients with central obesity has smaller controlled trial bases but consistent clinical observation. Patients with metabolic syndrome features (elevated waist circumference, insulin resistance, NAFLD) are common candidates. Provider intake covers cardiometabolic risk screening to confirm tesamorelin is the appropriate tool versus a GLP-1 (for broader weight loss) or a different protocol.

Tesamorelin for growth hormone optimization

Adult growth hormone production declines with age. Peak GH secretion occurs in adolescence and young adulthood; by age 50, GH secretion is typically 50 to 70 percent below young-adult peak. The decline is implicated in age-related changes in body composition (less lean mass, more fat mass), sleep quality, recovery from exertion, and skin texture.

Tesamorelin and other GHRH-pathway peptides are used to stimulate the body's own growth hormone release back toward younger-adult levels. The advantage over recombinant HGH is preserved feedback regulation: the body's own controls remain intact, reducing the risk of supraphysiological GH excess. Tesamorelin specifically has the advantage of the longest half-life among the GHRH analogs, supporting once-daily dosing versus the multiple daily injections required by shorter-acting options.

The tesamorelin and ipamorelin blend

The tesamorelin and ipamorelin combination is one of the most popular dual-pathway growth hormone stacks. The two peptides activate different receptors to produce a stronger and cleaner GH pulse than either alone.

Tesamorelin binds GHRH receptors on the anterior pituitary, telling the gland to release more growth hormone. Ipamorelin is a selective ghrelin receptor agonist that binds a different receptor and tells the gland to release more growth hormone via a parallel pathway. The two signals are additive at the pituitary, producing a larger total GH pulse than either peptide produces alone at the same dose.

Ipamorelin is also selective for the ghrelin receptor without significant cortisol or prolactin effect, which is a notable advantage over older ghrelin agonists. The selectivity makes the tesamorelin/ipamorelin stack cleaner than alternative combinations.

Rx Peps Direct prescribes the combination as Tesamorelin/Ipamorelin at 12mg tesamorelin + 6mg ipamorelin per vial, $120 per vial, covering approximately 4 to 6 weeks at typical dosing. The combination is a common choice for patients targeting body composition who want the dual-pathway advantage in one injection.

Tesamorelin vs sermorelin vs CJC-1295

Patients researching growth hormone peptides typically encounter all three molecules. Each has its place; the choice depends on goal and budget.

For deeper comparison see tesamorelin vs sermorelin. To pair tesamorelin with a subcutaneous-fat agent, see the AOD-9604 and tesamorelin stack.

Realistic dosing protocol

The FDA-approved Egrifta dose for HIV lipodystrophy is 2mg subcutaneous injection once daily, and that is the dose behind the 15 to 18 percent visceral fat results. Rx Peps Direct offers two doses from the 24mg / 3mL (8mg/mL) vial, and you choose when you order: the same 2mg, which is 25 units (0.25mL), or about 1mg, which is 13 units (0.13mL). Both are taken once at bedtime, Monday to Friday, with two days off each week. Neither the approved label nor the trials titrate, so you can start on either, and your prescriber reviews the dose you choose. About 1mg has not been tested for visceral fat.

Your prescriber can lower the dose: for a two-week tolerance start, for side effects (joint pain, swelling, numbness or tingling in the hands, rising home glucose readings), or for older or smaller patients and those with diabetes. Your prescriber can also set about 1mg on the 15mg / 5mL (3mg/mL) vial, which is 33 units (0.33mL) and is not something you choose at checkout. The label states the units for the vial you have. Plan on at least 26 weeks, then a review with your prescriber.

The two strengths are not interchangeable. Check the concentration on the label before every draw: 25 units of the 8mg/mL vial is 2mg; 25 units of the 3mg/mL vial is 0.75mg.

Why five days a week rather than seven: the pharmacy sends at most two vials per fill, and two vials hold 24 doses. On a five-day week that lasts almost five weeks; on a seven-day week it would run out in 24 days. Five days a week gives about 71 percent of the trial's weekly amount, so results may be smaller in proportion.

Injections go under the skin of the abdomen at bedtime, rotating sites, with a U-100 insulin syringe (a 0.3mL barrel reads a draw of up to 30 units most accurately; a 33-unit draw is more than a 0.3mL barrel holds and needs a larger one). Rx Peps Direct does not order lab work. If you have diabetes or prediabetes, send a recent HbA1c or fasting glucose from your own doctor before your first fill; everyone else starts without a test. Measure your waist at your belly button before your first dose, at week 12, and at week 26. If your waist has not changed by week 26, your prescriber will talk with you about stopping.

Side effects and safety

• Common: injection site reactions. Mild redness, swelling, or itching at injection site. Resolves within hours. Rotating sites reduces frequency.
• Common: muscle and joint aches in first 1 to 2 weeks. Mild aches as growth hormone levels rise. Message your provider; the usual step is lowering the dose, not stopping.
• Moderate: transient hyperglycemia. Growth hormone modestly raises blood sugar; insulin sensitivity may decline slightly. If you have prediabetes or diabetes, tell your prescriber before you start and send a recent HbA1c or fasting glucose from your own doctor before your first fill. Report rising home glucose readings.
• Moderate: mild edema or fluid retention. Swelling in the hands or feet, occasional in the first few weeks. Message your provider; the dose usually comes down.
• Rare: carpal tunnel symptoms. Reported at higher doses or in patients with predisposing factors. Message your provider about tingling or numbness in the hands; the dose usually comes down.
• How a dose comes down. Your prescriber can lower it, and the label states the units for the vial you have. Do not change the dose yourself.

Contraindications: active malignancy (GH may support tumor growth), a pituitary tumor, pregnancy and breastfeeding, severe untreated sleep apnea (GH may worsen), uncontrolled type 2 diabetes, type 1 diabetes (relative). Provider screens during intake.

Cost comparison

Research-grade tesamorelin is sold by online vendors labeled "for research use only" or "not for human consumption." The molecule is often similar but the source, sterility, identity verification, and provider supervision are not. For the regulatory and quality comparison see compounded peptides vs research peptides.

How to buy tesamorelin from Rx Peps Direct

1. Browse the muscle growth category and add tesamorelin to your protocol. Choose between:
   • Tesamorelin 24mg ($200 per vial): about 1mg (13 units, 1 vial a fill) or 2mg (25 units, 2 vials a fill), five nights a week. You choose, and your prescriber reviews it.
   • Tesamorelin/Ipamorelin 12mg+6mg ($120): dual-pathway GH stack.
2. Pay the $39 medical review at checkout and complete the clinical intake. Disclose current medications, health history, and goals.
3. A licensed clinician in your state reviews the intake. Dr. Jonathan Snipes, MD (Medical Director, NPI 1821250077) oversees clinical protocols. Kim Callender, NP signs the prescription after individual review.
4. The pharmacy compounds the vial, runs per-batch sterility and endotoxin testing, and texts a secure payment link for the medication at wholesale.
5. The vial ships pre-reconstituted via FedEx Overnight in a reusable cooled travel case. Insulin syringes, alcohol swabs, and the prescriber's written dosing protocol are included.

Ready to start

For cash-pay patients targeting visceral fat reduction, growth hormone optimization, or body composition goals, compounded tesamorelin delivers the same active molecule as branded Egrifta at a fraction of the cost. Browse Tesamorelin for the 2mg five-night protocol, or the Tesamorelin/Ipamorelin blend for the dual-pathway stack. For broader peptide category context see the peptide therapy overview.